Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of TQC2938 in moderate to severe chronic obstructive pulmonary disease
CTR20250079Phase 2Active
- Sponsor
- Nanjing Shunxin Pharmaceutical
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TQC2938 in chronic obstructive pulmonary disease (COPD), sponsored by Nanjing Shunxin Pharmaceutical. Started Mar 2025; status: active.
02
Drugs
TQC2938
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20250079.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250079.